Learn about the real-world utilization of bispecific antibodies for relapsed/refractory multiple myeloma in the US community oncology setting, showing promising results in patient characteristics and uptake, with potential impact on patient...
Learn about the real-world utilization of bispecific antibodies for relapsed/refractory multiple myeloma in the US community oncology setting, showing promising results in patient characteristics and uptake, with potential impact on patient...
On episode 6 of Oncology Innovations, host Gordon Kuntz sits down with Aimee Ginsburg, PharmD, McKesson Value Pathways, to discuss the value of clinical pathways in a world of rapidly advancing scientific data, and how decision support tools...
On episode 6 of Oncology Innovations, host Gordon Kuntz sits down with Aimee Ginsburg, PharmD, McKesson Value Pathways, to discuss the value of clinical pathways in a world of rapidly advancing scientific data, and how decision support tools...
Gordon Kuntz and Dan Rhodes, PhD, discuss genomic testing and next-generation sequencing, the available technologies advancing the precision model of care, and exciting steps forward in the rapidly evolving oncology treatment landscape.
Gordon Kuntz and Dan Rhodes, PhD, discuss genomic testing and next-generation sequencing, the available technologies advancing the precision model of care, and exciting steps forward in the rapidly evolving oncology treatment landscape.
Gordon Kuntz and Dan Rhodes, PhD, discuss genomic testing and next-generation sequencing, the available technologies advancing the precision model of care, and exciting steps forward in the rapidly evolving oncology treatment landscape.
Gordon Kuntz and Dan Rhodes, PhD, discuss genomic testing and next-generation sequencing, the available technologies advancing the precision model of care, and exciting steps forward in the rapidly evolving oncology treatment landscape.
Gordon Kuntz; Bryan Loy, MD, MBA; and Tushar Pandey, MBA, discusses the reimbursement landscape and payer perspective on precision medicine and diagnostics and how stakeholders assess value.
Gordon Kuntz; Bryan Loy, MD, MBA; and Tushar Pandey, MBA, discusses the reimbursement landscape and payer perspective on precision medicine and diagnostics and how stakeholders assess value.
Gordon Kuntz sits down with Ira Klein, MD, MBA, to discuss the need for industry standards in next-generation sequencing and comprehensive genomic profiling and how the lack of standards is impacting patients, providers, and payers.
Gordon Kuntz sits down with Ira Klein, MD, MBA, to discuss the need for industry standards in next-generation sequencing and comprehensive genomic profiling and how the lack of standards is impacting patients, providers, and payers.
Gordon Kuntz sits down with Carole Tremonti, RN, MBA, of Project Ronin to discuss clinical decision support and artificial intelligence and their role in cancer care.
Gordon Kuntz sits down with Carole Tremonti, RN, MBA, of Project Ronin to discuss clinical decision support and artificial intelligence and their role in cancer care.
Gordon Kuntz sits down with Bo Gamble of the Community Oncology Alliance to discuss the ASCO-COA Oncology Medical Home Model, which established core elements needed to deliver equitable, high-quality cancer care.
Gordon Kuntz sits down with Bo Gamble of the Community Oncology Alliance to discuss the ASCO-COA Oncology Medical Home Model, which established core elements needed to deliver equitable, high-quality cancer care.
Adam Feuerstein, national biotech columnist, STAT, provides a look into the complexity of reporting on biotech and health care advancements, the shift in STAT's editorial focus to COVID-19 coverage from a science and biotech perspective, and...
Adam Feuerstein, national biotech columnist, STAT, provides a look into the complexity of reporting on biotech and health care advancements, the shift in STAT's editorial focus to COVID-19 coverage from a science and biotech perspective, and...
Michael Sinha, MD, JD, MPH, dissects the legality of international and domestic travel bans from a health policy perspective, the nuances of state-level authority to enforce a lockdown, and more.
Michael Sinha, MD, JD, MPH, dissects the legality of international and domestic travel bans from a health policy perspective, the nuances of state-level authority to enforce a lockdown, and more.
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...